| Product name: |
Recombinant 2019-nCoV Papain-Like Protease |
| Description: |
Recombinant 2019-nCoV Papain-like Protease is produced by our E.coli expression system and the target gene encoding Glu1564-Lys1878 is expressed. |
| Accession: |
QHD43415.1 |
| Molecular weight: |
35.8 KDa |
| Apparent molecular weight: |
34 KDa, reducing conditions |
| Purity: |
Greater than 95% as determined by reducing SDS-PAGE. |
| Biological activity: |
Measured by its ability to convert the fluorogenic peptide substrate, Arg-Leu-Arg-Gly-Gly-AMC (RLRGGAMC) to RLRGG and 7-amino-4-methylcoumarin (AMC). The Specific Activity is 241.7 pmol/min/μg. |
| Storage: |
Store at ≤-70°C, stable for 6 months after receipt.
Store at ≤-70°C, stable for 3 months under sterile conditions after opening.
Please minimize freeze-thaw cycles. |
| Delivery condition: |
The product is shipped on dry ice/polar packs.
Upon receipt, store it immediately at the temperature listed below. |
| Background: |
Replication of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) requires proteolytic processing of the replicase polyprotein by two viral cysteine proteases, a chymotrypsin-like protease (3CLpro) and a papain-like protease (PLpro). These proteases are important targets for development of antiviral drugs that would inhibit viral replication and reduce mortality associated with outbreaks of SARS-CoV. PLpro is a cysteine protease located within the non-structural protein 3 (NS3) section of the viral polypeptide. PLPro activity is required to process the viral polyprotein into functional, mature subunits; specifically, PLPro cleaves a site at the amino-terminus of the viral replicase region. In addition to its role in viral protein maturation, PLPro possesses a deubiquitinating and deISGylating activity. In vivo, this protease antagonizes innate immunity by inhibiting IRF3-induced production of type I interferons. |
規(guī)格：
價(jià)格：
下載說(shuō)明 ①
在線咨詢
技術(shù)支持
